The Dutch Cancer Society (KWF Kankerbestrijding) has provided funding for an initiative that will assess an intraoperative molecular imaging technique for guiding prostate cancer surgery.
The Netherlands Cancer Institute (NKI), the University of Twente, luminescence imaging developer Lightpoint Medical, and Philips Healthcare are teaming up to evaluate Lightpoint's molecular imaging technology for imaging the prostate cancer biomarker prostate-specific membrane antigen (PSMA) during surgery. If the technology is successful, it will then be tested in larger clinical trials, according to Lightpoint.
The goal of the project is to spare healthy tissue and reduce recurrence rates in prostate cancer surgery, Lightpoint said.
